Abstract
Obesity is a predisposing factor in the development of a number of non-communicable diseases. The current Russian clinical guidelines for the treatment of obesity in adults include the following drugs: orlistat, sibutramine, sibutramine+metformin, liraglutide. Currently, hypoglycemic agents such as glucagon-like peptide-1 (GLP-1) agonists and incretin multi-agonists are being actively studied in the treatment of obesity, especially in comorbid patients. Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight among hypoglycemic drugs in a number of pilot and larger studies. The data obtained regarding the effectiveness of the above drugs indicate the need to expand existing clinical recommendations for the treatment of patients with obesity and introduce into clinical practice alternative drugs, the use of which is quite safe and well tolerated by patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call